Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25454005 | 0.88 | CARM1 (0.61) | KDM4ECARM1KMT2AMEN1HTT | |
| SCHEMBL9945969 | 0.87 | KDM4E (0.58) | KDM4ECARM1KMT2AMEN1HTT | |
| SCHEMBL25907878 | 0.86 | KDM4E (0.72) | KDM4ECARM1KMT2AMEN1HTT | |
| SCHEMBL19121936 | 0.86 | KDM4E (0.47) | KDM4ECARM1KMT2AMEN1HTT | |
| SCHEMBL20314859 | 0.85 | KDM4E (0.45) | KDM4ECARM1KMT2AMEN1HTT | |
| SCHEMBL9946027 | 0.82 | KMT2A (0.48) | KDM4ECARM1KMT2AMEN1HTT | |
| SCHEMBL13119614 | 0.81 | KDM4E (0.57) | KDM4ECARM1KMT2AMEN1HTT | |
| SCHEMBL22857118 | 0.81 | CARM1 (0.46) | KDM4ECARM1KMT2AMEN1HTT | |
| SCHEMBL13889405 | 0.81 | KDM4E (0.46) | KDM4ECARM1KMT2AMEN1HTT | |
| SCHEMBL19309248 | 0.80 | THRA (0.53) | KDM4ECARM1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | KDM4E 4270/4885CARM1 4297/4885KMT2A 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.